An APRIL to remember: novel TNF ligands as therape...[Nat Rev Drug Discov. 2006]

Search for

Advanced Search (beta)

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 1

Click to change filter selection through MyNCBI.

1: Nat Rev Drug Discov. 2006 Mar;5(3):235-46. Links

An APRIL to remember: novel TNF ligands as therapeutic targets.

Dillon SR, Gross JA, Ansell SM, Novak AJ.

Department of Autoimmunity and Inflammation, ZymoGenetics, Inc. 1201 Eastlake Avenue East, Seattle, Washington 98102, USA. dillons@zgi.com

Since their discovery in 1998, the two TNF family members APRIL and BLyS/BAFF have received increasing attention. In addition to regulating normal B-cell development and immune responses, these molecules might be crucial in a diverse set of diseases, including autoimmunity and cancer. Although more has been published about the general biology of BLyS/BAFF than that of APRIL, many recent articles have described novel APRIL biology. Here we focus on APRIL, exploring its normal and pathological functions, and comparing the therapeutic molecules currently under development that target BLyS/BAFF alone, or APRIL and BLyS/BAFF together.

PMID: 16474316 [PubMed - indexed for MEDLINE]

Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. [J Immunol. 2004]
Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. [Biochemistry. 2005]
Mechanism of BLyS action in B cell immunity. [Cytokine Growth Factor Rev. 2002]
The BAFF/APRIL system: life beyond B lymphocytes. [Mol Immunol. 2005]
BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. [J Immunol. 2002]
» See all Related Articles...

Display Show

An APRIL to remember: novel TNF ligands as therapeutic targets.

Related Articles